Patents by Inventor Lisheng Peng
Lisheng Peng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220154160Abstract: Disclosed herein is a botulinum neurotoxin (BoNT) polypeptide with a modified receptor binding domain (HC) having one or more amino acid mutations that modify the binding of the BoNT to the receptor. Specific mutations and combinations of mutations are also disclosed. Isolated modified HC, polypeptides comprising the modified HC, chimeric molecules, pharmaceutical compositions, and methods of making and using the same are also disclosed. Methods of identifying additional such modified receptor binding domains, are further disclosed.Type: ApplicationFiled: January 24, 2022Publication date: May 19, 2022Inventors: Min Dong, Lisheng Peng, Liang Tao
-
Patent number: 11268080Abstract: Disclosed herein is a botulinum neurotoxin (BoNT) polypeptide with a modified receptor binding domain (HC) having one or more amino acid mutations that modify the binding of the BoNT to the receptor. Specific mutations and combinations of mutations are also disclosed. Isolated modified HC, polypeptides comprising the modified HC, chimeric molecules, pharmaceutical compositions, and methods of making and using the same are also disclosed. Methods of identifying additional such modified receptor binding domains, are further disclosed.Type: GrantFiled: March 25, 2016Date of Patent: March 8, 2022Assignee: President and Fellows of Harvard CollegeInventors: Min Dong, Lisheng Peng, Liang Tao
-
Patent number: 10844362Abstract: Disclosed herein are botulinum neurotoxin (BoNT) polypeptides with a modified receptor binding domain of Clostridial botulinum serotype B (B-Hc), comprising one or more substitution mutations corresponding to substitution mutations in serotype B, strain 1, V1118M; Y1183M; E1191M; E1191I; E1191Q; E1191T; S1199Y; S1199F; S1199L; S1201V; or combinations thereof. Specific combination mutations include E1191M and S1199L, E1191M and S1199Y, E1191M and S1199F, E1191Q and S1199L, E1191Q and S1199Y, or E1191Q and S1199F. Other substitution mutations are also disclosed. Isolated modified receptor binding domains, chimeric molecules, pharmaceutical compositions, and methods of using the same are also disclosed.Type: GrantFiled: January 18, 2019Date of Patent: November 24, 2020Assignee: President and Fellows of HarvardInventors: Min Dong, Lisheng Peng, Pål Erik Gustav Stenmark, Ronnie Per Arne Berntsson
-
Publication number: 20190256834Abstract: Disclosed herein are botulinum neurotoxin (BoNT) polypeptides with a modified receptor binding domain of Clostridial botulinum serotype B (B-Hc), comprising one or more substitution mutations corresponding to substitution mutations in serotype B, strain 1, V1118M; Y1183M; E1191M; E11911; E1119JQ; E1191T; S1199Y; S1199F; S1199L; S1201V; or combinations thereof. Specific combination mutations include E1191M and S1199L, E1191M and S1199Y, E1191M and S1199F, E1191Q and S1199L, E1191Q and S1199Y, or E1191Q and S1199F. Other substitution mutations are also disclosed. Isolated modified receptor binding domains, chimeric molecules, pharmaceutical compositions, and methods of using the same are also disclosed.Type: ApplicationFiled: January 18, 2019Publication date: August 22, 2019Inventors: Min Dong, Lisheng Peng, Pål Erik Gustav Stenmark, Ronnie Per Arne Berntsson
-
Patent number: 10190110Abstract: Disclosed herein are botulinum neurotoxin (BoNT) polypeptides with a modified receptor binding domain of Clostridial botulinum serotype B (B-Hc), comprising one or more substitution mutations corresponding to substitution mutations in serotype B, strain 1, V1118M; Y1183M; E1191M; E1191I; E1191Q; E1191T; S1199Y; S1199F; S1199L; S1201V; or combinations thereof. Specific combination mutations include E1191M and S1199L, E1191M and S1199Y, E1191M and S1199F, E1191Q and S1199L, E1191Q and S1199Y, or E1191Q and S1199F. Other substitution mutations are also disclosed. Isolated modified receptor binding domains, chimeric molecules, pharmaceutical compositions, and methods of using the same are also disclosed.Type: GrantFiled: February 13, 2017Date of Patent: January 29, 2019Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Min Dong, Lisheng Peng, Pål Erik Gustav Stenmark, Ronnie Per Arne Berntsson
-
Publication number: 20180080016Abstract: Disclosed herein is a botulinum neurotoxin (BoNT) polypeptide with a modified receptor binding domain (HC) having one or more amino acid mutations that modify the binding of the BoNT to the receptor. Specific mutations and combinations of mutations are also disclosed. Isolated modified HC, polypeptides comprising the modified HC, chimeric molecules, pharmaceutical compositions, and methods of making and using the same are also disclosed. Methods of identifying additional such modified receptor binding domains, are further disclosed.Type: ApplicationFiled: March 25, 2016Publication date: March 22, 2018Inventors: Min Dong, Lisheng Peng, Liang Tao
-
Publication number: 20170226496Abstract: Disclosed herein are botulinum neurotoxin (BoNT) polypeptides with a modified receptor binding domain of Clostridial botulinum serotype B (B-Hc), comprising one or more substitution mutations corresponding to substitution mutations in serotype B, strain 1, V1118M; Y1183M; E1191M; E1191I; E1191Q; E1191T; S1199Y; S1199F; S1199L; S1201V; or combinations thereof. Specific combination mutations include E1191M and S1199L, E1191M and S1199Y, E1191M and S1199F, E1191Q and S1199L, E1191Q and S1199Y, or E1191Q and S1199F. Other substitution mutations are also disclosed. Isolated modified receptor binding domains, chimeric molecules, pharmaceutical compositions, and methods of using the same are also disclosed.Type: ApplicationFiled: February 13, 2017Publication date: August 10, 2017Inventors: Min Dong, Lisheng Peng, Pål Erik Gustav Stenmark, Ronnie Per Arne Berntsson
-
Patent number: 9598685Abstract: Disclosed herein are botulinum neurotoxin (BoNT) polypeptides with a modified receptor binding domain of Clostridial botulinum serotype B (B-Hc), comprising one or more substitution mutations corresponding to substitution mutations in serotype B, strain 1, V1118M; Y1183M; E1191M; E1191I; E1191Q; E1191T; S1199Y; S1199F; S1199L; SI 20 IV; or combinations thereof. Specific combination mutations include E1 191M and S1199L, E1191M and S1199Y, E1191M and S1199F, E1191Q and S1199L, E1191Q and S 1199Y, or E 1191 Q and S 1199F. Other substitution mutations are also disclosed. Isolated modified receptor binding domains, chimeric molecules, pharmaceutical compositions, and methods of using the same are also disclosed.Type: GrantFiled: March 13, 2013Date of Patent: March 21, 2017Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Min Dong, Lisheng Peng, Pål Erik Gustav Stenmark, Ronnie Per Arne Berntsson
-
Publication number: 20150166972Abstract: Disclosed herein are botulinum neurotoxin (BoNT) polypeptides with a modified receptor binding domain of Clostridial botulinum serotype B (B-Hc), comprising one or more substitution mutations corresponding to substitution mutations in serotype B, strain 1, V1118M; Y1183M; E1191M; E1191I; E1191Q; E1191T; S1199Y; S1199F; S1199L; SI 20 IV; or combinations thereof. Specific combination mutations include E1 191M and S1199L, E1191M and S1199Y, E1191M and S1199F, E1191Q and S1199L, E1191Q and S 1199Y, or E 1191 Q and S 1199F. Other substitution mutations are also disclosed. Isolated modified receptor binding domains, chimeric molecules, pharmaceutical compositions, and methods of using the same are also disclosed.Type: ApplicationFiled: March 13, 2013Publication date: June 18, 2015Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Min Dong, Lisheng Peng, Pål Erik Gustav Stenmark, Ronnie Per Arne Berntsson
-
Patent number: 7294697Abstract: In this invention, three genes encoding short chain neurotoxin are obtained by sea snake—Lapemis hardwickii venom gland cDNA library construction and DNA sequencing, named sn12, sn36, and sn160, respectively. The three genes are modified and amplified by PCR method, then cloned into expression vector PETTRX. The three neurotoxin genes are all highly expressed in soluble fusion protein in E. coli stain BL21-DE3 which is used as a expression host when induced with IPTG. Studies on the analgesic effects of the three recombinant short chain neurotoxins showed that three proteins, SN12, SN36 and SN160 all can significantly increase the pain threshold value of mouse.Type: GrantFiled: September 14, 2001Date of Patent: November 13, 2007Assignee: Zhongshan UniversityInventors: Anlong Xu, Xiaofen Zhong, Lisheng Peng, Jianwen Wei, Wenyan Wu, Wenli Yang
-
Publication number: 20050232913Abstract: In this invention, three genes encoding short chain neurotoxin are obtained by sea snake—Lapemis hardwickii venom gland cDNA library construction and DNA sequencing, named sn12, sn36, and sn160, respenctively. The three genes are modified and amplified by PCR method, then cloned into expression vector PETTRX. The three neurotoxin genes are all highly expressed in soluble fusion protein in E. coli stain BL21-DE3 which is used as a expression host when induced with IPTG. Studies on the analgesic effects of the three recombinant short chain neurotoxins showed that three proteins, SN12, SN36 and SN160 all can significantly increase the pain threshold value of mouse.Type: ApplicationFiled: September 14, 2001Publication date: October 20, 2005Inventors: Anlong Xu, Xiaofen Zhong, Lisheng Peng, Jianwen Wei, Wenyan Wu, Wenli Yang